These are really a first cut of the Phase-III results.
The announcement tells is: "a more detailed analysis of the Phase-III results by the end of the first quarter 2010.."
What we aren't seeing here is the % of patients with a viral load > 400 copies per ml. (as we will see when more details are out).
What we are seeing is that the CD4 count for Phase-III matches that of Phase-II.
So if we wanted the big bang, we're getting more sedate little bangs.
Do I understand correctly that this trial is now closed and there won't be any Phase-III 48 week data? Or is that yet to be determined once the regulators look over the 24 week data?
Big issue now is: what developments for commercialisation?
AVX Price at posting:
15.5¢ Sentiment: ST Buy Disclosure: Held